CN115177573B

CN115177573B - Eye muscle base solution and preparation method thereof

Info

Publication number: CN115177573B
Application number: CN202210967402.3A
Authority: CN
Inventors: 招敏聪; 田佳佳; 李璐; 贺锐
Original assignee: Plant Doctor Guangdong Biotechnology Co ltd
Current assignee: Plant Doctor Guangdong Biotechnology Co ltd
Priority date: 2022-08-12
Filing date: 2022-08-12
Publication date: 2023-03-14
Anticipated expiration: 2042-08-12
Also published as: CN115177573A

Abstract

The invention relates to the technical field of eye cosmetics, in particular to eye muscle base solution and a preparation method thereof. The eye muscle base solution contains 0.01-10% of Fucus vesiculosus extract, 0.01-12% of Boussingaultia extract, 0.01-10% of Fossilia latifolia extract, 0.01-15% of Panax schinseng extract and 0.01-12% of Lithospermum erythrorhizon extract. The plant extracts can be matched with each other to achieve the effects of moisturizing, resisting oxidation and wrinkles and repairing the cutin skin of the eyes.

Description

Eye muscle base solution and preparation method thereof

Technical Field

The invention relates to the technical field of eye cosmetics, in particular to eye muscle base solution and a preparation method thereof.

Background

The skin of the human eye loses elasticity with aging, which is a result of the combined action of factors such as living habits and normal aging of cells. Some external environmental factors can also accelerate the natural aging of the eye skin, such as ultraviolet irradiation and air pollution; all of the intrinsic, extrinsic and mechanical factors of the skin cause deterioration of the skin structure and function. And the eye muscle base solution is a cosmetic product formed under the thrust of the above factors.

Most of the eye muscle base solution contains hydrophilic and lipophilic components, and can break down water and oil in the skin care product simultaneously, so that the skin can absorb the moisture and oil better. The skin base liquid is used before essence and cream, and the smearing method is the same as that of essence or cream. However, the existing eye muscle foundation liquid has few types and quantities and single effect, and is difficult to solve the problems of moisturizing, anti-oxidation, anti-wrinkle and eye cutin skin repairing effects of eye skin in one step.

Disclosure of Invention

In order to achieve the purposes of moisturizing, antioxidation, wrinkle resistance and eye cutin skin repair, the invention provides an eye muscle base solution and a preparation method thereof.

In one aspect, the invention provides an eye muscle base solution comprising an fucus extract, a panax notoginseng extract, a eupatorium fortunei extract, a panax sanguinea extract, and a lithospermum erythrorhizon extract.

Preferably, the muscle base fluid contains the following components in percentage by mass: 0.01-10% of fucus extract, 0.01-12% of panax notoginseng extract, 0.01-10% of flonica villosa extract, 0.01-15% of panax sanguinea extract and 0.01-12% of lithospermum extract.

Preferably, the amount of the fucus extract is 0.01%, 0.02%, 0.05%, 0.08%, 0.1%, 0.2%, 0.5%, 0.8%, 1.0%, 1.2%, 1.5%, 1.7%, 2.0%, 2.2%, 2.5%, 2.8%, 3%, 3.5%, 4%, 4.5%, 5%, 6%, 7%, 8%, 9%, 10% or a range between any two of the above values, as mass% of the muscle base solution.

Preferably, the amount of the vervain extract is 0.01%, 0.02%, 0.05%, 0.08%, 0.1%, 0.2%, 0.5%, 0.8%, 1.0%, 1.2%, 1.5%, 1.7%, 2.0%, 2.2%, 2.5%, 2.8%, 3%, 3.5%, 4%, 4.5%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12% or a range between any two of the above values, as mass% of the muscle base solution.

Preferably, the amount of the sanguinea extract is 0.01%, 0.02%, 0.05%, 0.08%, 0.1%, 0.2%, 0.5%, 0.8%, 1.0%, 1.2%, 1.5%, 1.7%, 2.0%, 2.2%, 2.5%, 2.8%, 3%, 3.5%, 4%, 4.5%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15% by mass of the muscle base fluid, or a range between any two of the above values.

Preferably, the comfrey extract is used in an amount of 0.01%, 0.02%, 0.05%, 0.08%, 0.1%, 0.2%, 0.5%, 0.8%, 1.0%, 1.2%, 1.5%, 1.7%, 2.0%, 2.2%, 2.5%, 2.8%, 3%, 3.5%, 4%, 4.5%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12% or in a range between any two of the above values, as a mass percentage of the muscle base solution.

Preferably, the muscle base fluid contains the following components in percentage by mass: 0.01-8% of fucus extract, 0.02-10% of panax notoginseng extract, 0.05-7% of flonicandra extract, 0.05-10% of panax japonicus extract and 0.1-8% of lithospermum extract.

Preferably, the muscle base fluid contains the following components in percentage by mass: 0.05-6% of fucus extract, 0.08-8% of panax notoginseng extract, 0.1-6% of flonica villosa extract, 0.05-8% of panax sanguinea extract and 0.1-7% of lithospermum extract.

Preferably, the muscle base fluid contains the following components in percentage by mass: 0.1-5% of fucus extract, 0.2-6% of panax notoginseng extract, 0.5-5% of flonica villosa extract, 0.2-6% of panax sanguinea extract and 0.8-6% of lithospermum extract.

Preferably, the muscle base fluid contains water, and the water can be at least one selected from deionized water, distilled water and tap water. The muscle base solution contains 30-85% of water, 35-85% of water, 45-85% of water, 50-85% of water, 45-80% of water, 50-85% of water, 50-80% of water, 55-85% of water, 55-80% of water and the like.

Preferably, the muscle base fluid contains paramylon. The weight ratio of euglena gracilis polysaccharide in the muscle base solution is 0.01-5%, 0.1-5%, 0.2-4.5%, 0.5-4%, 0.5-3.5%, 0.6-3%, 0.6-2.5% and the like.

Preferably, the muscle base fluid comprises inositol. The myoinositol in the muscle base solution accounts for 0.02-4.5%, 0.1-4.5%, 0.2-4.5%, 0.5-4%, 0.5-3.5%, 0.6-3%, 0.8-2.5% and the like by mass.

Preferably, the muscle base fluid contains glycerol. The mass ratio of glycerol in the muscle base solution is 0.5-5%, 0.5-4.5%, 1-4%, 1-3.5%, 1-3% and the like.

Preferably, the muscle base fluid contains glycosaminoglycans. The muscle foundation solution contains 0.5-5 wt% of glucosaminoglycan, 0.5-4.5 wt%, 1-4 wt%, 1-3.5 wt%, 1-3 wt%, etc.

Preferably, the muscle base fluid contains PEG/PPG-20/5 polydimethylsiloxane. The mass ratio of PEG/PPG-20/5 dimethyl silicone polymer in the muscle base solution is 0.1-3%, 0.1-4.5%, 0.1-4%, 0.5-3.5%, 1-3% and the like.

Preferably, the muscle base fluid contains phenoxyethanol. The mass ratio of phenoxyethanol in the muscle base solution is 0.01-0.2%, 0.05-0.2%, 0.1-0.2% and the like.

Preferably, the muscle base fluid contains methyl gluceth-20. The mass ratio of the methyl glucitol polyether-20 in the muscle base solution is 0.5-4%, 0.8-4%, 1-3.5%, 1.5-3.5%, 2-3% and the like.

Preferably, the muscle base fluid contains allantoin. The mass ratio of allantoin in the muscle base fluid is 0.5-4%, 0.8-4%, 1-3.5%, 1.5-3.5%, 2-3% and the like.

Preferably, the muscle base fluid comprises oat kernel oil. The muscle base solution contains 0.1-3 wt% of oat kernel oil, 0.2-3 wt% of oat kernel oil, 0.5-2.2 wt% of oat kernel oil, 0.5-2 wt% of oat kernel oil and the like.

Preferably, the muscle base fluid contains carbomer. The mass ratio of carbomer in the muscle base solution is 0.2-3%, 0.2-2.5%, 0.2-2%, 0.5-3%, 0.5-2.5%, 1-3% and the like.

Preferably, the muscle fluid base contains sorbitan sesquioleate. The mass ratio of sorbitan sesquioleate in the muscle base solution is 0.2-3%, 0.2-2.5%, 0.2-2%, 0.5-3%, 0.5-2.5%, 1-3% and the like.

Preferably, the muscle base fluid contains tocopherol. The mass ratio of the tocopherol in the muscle base solution is 0.5-3.5%, 0.5-3%, 0.5-2.5%, 1-3%, 1-2.5%, 1.5-3% and the like.

Preferably, the muscle base fluid further comprises the following substances in percentage by mass of the muscle base fluid: 0.01-5% euglena gracilis polysaccharide, 0.02-4.5% inositol, 0.5-5% glycerol, 0.5-5% glycosaminoglycans, 0.1-3% PEG/PPG-20/5 dimethicone, 0.01-0.2% phenoxyethanol, 0.5-4% methyl gluceth-20, 0.5-4% allantoin, 0.1-3% oat kernel oil, 0.2-3% carbomer, 0.2-3% sorbitan sesquioleate, 0.5-3.5% tocopherol, 30-85% water.

Preferably, the muscle base fluid further comprises the following substances in percentage by mass of the muscle base fluid: 0.1-5% euglena gracilis polysaccharide, 0.2-4.5% inositol, 0.5-4.5% glycerol, 0.5-4.5% glycosaminoglycans, 0.2-3% PEG/PPG-20/5 dimethicone, 0.05-0.2% phenoxyethanol, 0.5-3.5% methyl gluceth-20, 0.5-3.5% allantoin, 0.5-3% oat kernel oil, 0.2-2.5% carbomer, 0.2-2.5% sorbitan sesquioleate, 0.5-3% tocopherol, 40-85% water.

Preferably, the eye muscle base fluid contains the following components in percentage by mass: 0.01-10% of fucus extract, 0.01-12% of panax notoginseng extract, 0.01-10% of flonica villosa extract, 0.01-15% of panax sanguinea extract, 0.01-12% of lithospermum extract, 0.01-5% of euglena gracilis polysaccharide, 0.02-4.5% of inositol, 0.5-5% of glycerol, 0.5-5% of glycosaminoglycans,

0.1-3% of PEG/PPG-20/5 polydimethylsiloxane, 0.01-0.2% of phenoxyethanol, 0.5-4% of methyl gluceth-20, 0.5-4% of allantoin, 0.1-3% of oat kernel oil, 0.2-3% of carbomer, 0.2-3% of sorbitan sesquioleate, 0.5-3.5% of tocopherol, 30-85% of water.

Preferably, the eye muscle base fluid contains the following components in percentage by mass: 0.01-8% fucus extract, 0.02-10% gynura segetum extract, 0.05-7% yucca schidigera extract, 0.05-10% sanguinea extract, 0.1-8% lithospermum extract, 0.01-5% euglena polysaccharide, 0.02-4.5% inositol, 0.5-5% glycerol, 0.5-5% glycosaminodextran, 0.1-3% PEG/PPG-20/5 polydimethylsiloxane, 0.01-0.2% phenoxyethanol, 0.5-4% methyl glucitol polyether-20, 0.5-4% allantoin, 0.1-3% oat kernel oil, 0.2-3% carbomer, 0.2-3% sorbitan sesquioleate, 0.5-3.5% tocopherol, 30-85% water.

Preferably, the eye muscle base fluid contains the following components in percentage by mass: 0.05-6% of fucus extract, 0.08-8% of panax notoginseng extract, 0.1-6% of yucca schidigera extract, 0.05-8% of sanguisorba extract, 0.1-7% of lithospermum extract, 0.01-5% of euglena minutissima polysaccharide, 0.02-4.5% of inositol, 0.5-5% of glycerol, 0.5-5% of glycosaminoglucan, 0.1-3% of PEG/PPG-20/5 polydimethylsiloxane, 0.01-0.2% of phenoxyethanol, 0.5-4% of methyl glucitol polyether-20, 0.5-4% of allantoin, 0.1-3% of oat kernel oil, 0.2-3% of carbomer, 0.2-3% of sorbitan sesquioleate, 0.5-3.5% of tocopherol, and 30-85% of water.

Preferably, the eye muscle base fluid contains the following components in percentage by mass: 0.1-5% of fucus extract, 0.2-6% of panax notoginseng extract, 0.5-5% of yucca schidigera extract, 0.2-6% of sanguisorba extract, 0.8-6% of lithospermum extract, 0.01-5% of euglena minuta polysaccharide, 0.02-4.5% of inositol, 0.5-5% of glycerol, 0.5-5% of glycosaminoglucan, 0.1-3% of PEG/PPG-20/5 polydimethylsiloxane, 0.01-0.2% of phenoxyethanol, 0.5-4% of methyl glucitol polyether-20, 0.5-4% of allantoin, 0.1-3% of oat kernel oil, 0.2-3% of carbomer, 0.2-3% of sorbitan monooleate, 0.5-3.5% of tocopherol, and 30-85% of water.

In another aspect, the present invention provides a method for preparing an ophthalmic muscle base solution, wherein the method can be prepared by conventional processes, for example, by mixing the raw materials; mixing can be carried out by heating or normal temperature. Specifically, the preparation method comprises the step of stirring the raw materials under heating.

Preferably, the preparation method of the muscle base fluid comprises the following steps: mixing the raw materials, heating and stirring.

Preferably, the heating temperature is 25-85 deg.C, 30-80 deg.C, 35-75 deg.C, 40-70 deg.C, 45-65 deg.C, etc.

Preferably, the stirring speed is 100-5000 r/min, 500-4000 r/min, 500-3000 r/min, 500-2000 r/min and the like.

Preferably, the stirring time is 0.2 to 5 hours, 0.5 to 4 hours, 0.5 to 3.5 hours, 0.5 to 3 hours, 1 to 3 hours, or the like.

Preferably, the preparation method of the muscle base fluid comprises the following steps: mixing the raw materials of the muscle base solution, heating to 25-85 ℃, stirring at the stirring speed of 100-5000 r/min, and stopping stirring after stirring for 0.2-5 hours to obtain the muscle base solution.

Has the advantages that:

the eye muscle base solution contains fucus extract, panax notoginseng extract, floppinum extract, panax sanguinea extract and lithospermum extract of natural plant extracts; the plant extracts can be matched with each other to obtain the effects of moisturizing, resisting oxidation and wrinkles and repairing the cutin skin of the eyes.

The skin base solution comprises the fucus extract, the yucca schidigera extract and the lithospermum extract, and has synergistic effect, so that the increase of lamellar bodies and the transfer of stratum corneum lipid are promoted, the regeneration of cutin can be effectively regulated, the cutin barrier of the skin is strengthened, and the skin resistance is improved.

The gynura segetum extract, the panax quinquefolius extract and the lithospermum extract are mutually matched, so that the skin moisturizing and water holding effects of the muscle base solution are improved, the moisture maintenance and absorption of the skin are promoted, the skin moisturizing effect can be effectively adjusted, and the dryness resisting, moisturizing and water holding capacities of the eye skin are enhanced and improved.

The gynura segetum extract and the eupatorium floribundum extract are cooperatively and mutually matched, so that the production of skin elastin can be effectively promoted, the anti-wrinkle effect of skin is adjusted, and the beauty and the flatness of the skin are enhanced.

Detailed Description

The present invention will be described in detail below with reference to specific embodiments and examples, and the advantages and various effects of the present invention will be more clearly apparent therefrom. It will be understood by those skilled in the art that these specific embodiments and examples are illustrative of the invention and are not to be construed as limiting the invention.

Throughout the specification, unless otherwise specifically noted, terms used herein should be understood as having meanings as commonly used in the art. Accordingly, unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. If there is a conflict, the present specification will control.

Unless otherwise specifically indicated, various raw materials, reagents, instruments, equipment and the like used in the present invention may be commercially available or may be prepared by existing methods.

The components and the amounts (mass percentages) of the ocular muscle base solutions of the examples and comparative examples of the present invention are as follows:

table 1: example and comparative example compositions

The preparation method of the muscle base fluid of the examples and comparative examples in the above table comprises: the following steps are carried out: fucus vesiculosus extract, gynura segetum extract, philadelphia floribunda extract, sanguinea japonica extract, lithospermum extract, euglena minutissima polysaccharide, inositol, glycerol, glycosaminoglycans, PEG/PPG-20/5 polydimethylsiloxane, phenoxyethanol, methyl gluceth-20, allantoin, oat kernel oil, carbomer, sorbitan sesquioleate, tocopherol and water are mixed, then the mixture is heated to 55 ℃ and stirred at the stirring speed of 1000 revolutions per minute, and the stirring is stopped after stirring for 1 hour, so that the muscle base solution of the above examples and comparative examples can be obtained.

The muscle base solutions of the above examples and comparative examples were tested.

1. Stratum corneum barrier repair test: the effect of the application of the muscle base fluid of examples 1 to 4 and comparative examples 1 to 10 on the stratum corneum barrier repair was examined by skin lamellar body repair.

Experimental theoretical knowledge: when the skin barrier is acutely damaged, the stratum granulosum cells quickly secrete and form precursor lamellar bodies, so that the quantity of the lamellar bodies in a short term is reduced, lipid transfer is inhibited, and the primary repair of the stratum corneum lipid membrane is achieved. The newly generated lamellar bodies then appear in the stratum granulosum and act rapidly until the permeability barrier function is restored.

The experimental steps are as follows: 20 volunteers without active skin diseases are selected for the experiment, and before the experiment, the volunteers wash the two forearms with clear water and sit still for 60min in an environment with the temperature of 25 +/-2 ℃ and the relative humidity of 50 +/-5 percent. Selecting 15 parts of the forearm flexor side of the volunteer, taking one of the parts as a blank control, wherein each part is 2cm multiplied by 2cm in size, carrying out tape pasting (the tape pasting not only reduces horny cells and intercellular lipid of horny layer, but also thins the horny layer, so that mechanical damage occurs to the skin barrier), pasting each part for 20 times, keeping the pasting time, pressure and tape tearing speed and direction consistent, and recording the quantity L0 of lamellar bodies at the moment. The muscle fluid of the test specimen was then applied to 14 sites, and at 60min, the number of lamellar bodies L1 at that time was recorded. Finally, the change rate eta of the lamellar body = [ (L1-L0)/L0 ]. Times 100% is obtained. Among them, the stratum corneum barrier repair test results of examples and comparative examples are shown in table 2:

table 2: test results for stratum corneum barrier repair

From the test data, the eye muscle base solutions prepared in the application examples 1 to 4 of the present invention have a good skin repair effect, and can strongly repair the eye skin to maintain healthy eye skin. Among them, the repairing ability of example 4 is the best. Compared with the comparative examples 1-4 and the example 4, the fucus extract, the yucca schidigera extract and the lithospermum extract are matched with each other, so that the muscle foundation fluid has a good eye skin repairing and maintaining effect; when the total amount of the fucus extract, the flolan floribunda extract and the lithospermum erythrorhizon extract in the comparative examples 1-4 is not changed, the fucus extract, the flolan floribunda extract and the lithospermum erythrorhizon extract are changed mutually, the skin repairing effect of the obtained comparative example products is poorer than that of the example 4, and the synergistic compounding effect of the fucus extract, the flolan floribunda extract and the lithospermum erythrorhizon extract obviously improves the skin repairing and maintaining effects of the muscle foundation liquid. The components of the muscle base solution of the invention, namely the fucus extract, the florida extract and the lithospermum extract, have synergistic effect, promote the increase of lamellar bodies and the transfer of stratum corneum lipid, effectively regulate the regeneration of cutin, strengthen the cutin barrier of skin and improve the resistance of skin.

2. And (3) testing the moisturizing effect: 140 volunteers were selected and randomly divided into 14 groups of 10 persons (5 males and 5 females) per group. The subject, after cleaning the eye skin, was dried and then applied with the muscle base solutions of examples and comparative examples, respectively: measuring facial water content in an environment with temperature of 25 + -2 deg.C and relative humidity of 50 + -5%, measuring facial skin water content before and after applying muscle base solution for 6 hr with CM825 tester provided by German CK company, respectively, recording the results, and averaging; wherein 8 drops of muscle base liquid are evenly applied to the skin near the eyelid of each eye in two drops at 2 times when the muscle base liquid is used by the volunteer.

The moisturizing effect test results are shown in table 3 below:

table 3: test of moisturizing Effect

From the test data, the eye muscle base solutions prepared in the application examples 1 to 4 of the present invention have a good moisture retention effect, and can perform moisture retention maintenance on eye skin, maintain sufficient moisture of the eye skin, and maintain the moisture effect of the eye skin. Among them, comparison of comparative examples 5-8 with example 4 shows that the gynura segetum extract, the panax japonicus extract and the lithospermum extract of the invention are mutually matched, so that the foundation liquid of the invention has good eye skin moisturizing and water retention effects; when the total amount of the gynura segetum extract, the panax quinquefolius extract and the lithospermum extract in the comparative examples 5-8 is unchanged, the using amounts or the types of the gynura segetum extract, the panax quinquefolius extract and the lithospermum extract are changed mutually, the skin repairing effect of the obtained comparative example products is poorer than that of the comparative example 4, and the gynura segetum extract, the panax quinquefolius extract and the lithospermum extract generate a synergistic compounding effect to remarkably increase the skin moisturizing and water retention effects of the muscle base fluid. The muscle base solution disclosed by the invention has synergistic effects of the panax notoginseng extract, the panax sanguinea extract and the lithospermum extract, promotes the maintenance and absorption of moisture of skin, can effectively regulate the skin moistening effect, and strengthens and improves the dryness resisting, moisturizing and water holding capacities of eye skin.

3. Wrinkle change test: 280 volunteers were selected into 14 groups of 20 persons each (of which 10 were male and 10 were female). The skin wrinkle change test was performed on the muscle base solutions of examples and comparative examples, respectively. Before testing, volunteers cleaned eye skin with the same cleaning product; then 14 groups of volunteers are evenly smeared on the skin near the eyes for 1 time in the morning and at night each day, the smearing quantity of the skin near the eyelids of each eye is 3 drops each time, and after 2 months of continuous use; the skin sites near the ocular skin of the subjects were washed and the ocular skin wrinkle changes were analyzed using a VISIA facial image analyzer, usa, at an ambient temperature of 25 ± 2 ℃ and a humidity of 50 ± 5% to test the effect of the example and comparative example muscle base solutions on the removal of ocular wrinkles. The test results are set forth in table 4 below:

table 4: wrinkle Change test results

Test set	Reduction rate of wrinkles
		Example 1	51.4％
Example 2	52.3％
		Example 3	54.6％
Example 4	54.9％
		Comparative example 1	46.3％
Comparative example 2	45.9％
		Comparative example 3	46.5％
Comparative example 4	45.7％
		Comparative example 5	44.8％
Comparative example 6	45.0％
		Comparative example 7	44.6％
Comparative example 8	44.1％
		Comparative example 9	39.7％
Comparative example 10	38.5％

According to the test data, the eye muscle base solution prepared in the application examples 1 to 4 has a good antioxidant effect, can achieve an anti-wrinkle effect on eye skin, and can maintain the flatness and beauty of the eye skin. Among them, example 4 is the best in antioxidant and wrinkle-resistant effects. Wherein, the comparison of the comparative examples 9-10 with the example 4 shows that the gynura segetum extract and the arundina floribunda extract are matched with each other, so that the muscle base fluid has good wrinkle-resisting and oxidation-resisting effects on eye skin; when the total amount of the gynura segetum extract and the flossy orchid extract in the 9-10 comparative examples is unchanged, the types and the dosages of the gynura segetum extract and the flossy orchid extract are changed mutually, the wrinkle resisting and oxidation resisting effects of the obtained comparative example products are poorer than those of the comparative example 4, and the synergistic compounding effect of the gynura segetum extract and the flossy orchid extract remarkably improves the wrinkle resisting and maintaining effects of the muscle base fluid on the skin. The muscle base solution disclosed by the invention has the synergistic effects of the panax notoginseng extract and the yucca schidigera extract, promotes the production of skin elastin, can effectively regulate the anti-wrinkle effect of skin, and strengthens the beauty and the flatness of the skin.

Finally, it should be further noted that the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus.

While preferred embodiments of the present invention have been described, additional variations and modifications in those embodiments may occur to those skilled in the art once they learn of the basic inventive concepts. Therefore, it is intended that the appended claims be interpreted as including the preferred embodiment and all changes and modifications that fall within the scope of the invention.

It will be apparent to those skilled in the art that various changes and modifications may be made in the present invention without departing from the spirit and scope of the invention. Thus, if such modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include such modifications and variations.

Claims

1. An ocular muscle base fluid, comprising: the composite material comprises the following raw materials in percentage by mass: 0.05-6% fucus extract, 0.08-8% gynura segetum extract, 0.1-6% yucca schidigera extract, 0.05-8% sanguinea extract, 0.1-7% lithospermum extract, 0.01-5% euglena polysaccharide, 0.02-4.5% inositol, 0.5-5% glycerol, 0.5-5% glycosaminodextran, 0.1-3% PEG/PPG-20/5 polydimethylsiloxane, 0.01-0.2% phenoxyethanol, 0.5-4% methyl glucitol polyether-20, 0.5-4% allantoin, 0.1-3% oat kernel oil, 0.2-3% carbomer, 0.2-3% sorbitan sesquioleate, 0.5-3.5% tocopherol, 30-85% water.

2. The ocular muscle base solution of claim 1, wherein: the water is at least one selected from deionized water, distilled water and tap water.

3. The method for preparing ocular muscle base fluid according to any one of claims 1 to 2, wherein: the preparation method comprises the following steps: the muscle base solution can be obtained by mixing, heating and stirring the raw materials of the muscle base solution.

4. The method for preparing an ocular muscle base fluid according to claim 3, wherein: the heating temperature is 25-85 ℃.

5. The method for preparing an ocular muscle base fluid according to claim 3, wherein: the stirring time is 0.2-5 hours, and the stirring speed is 100-5000 r/min.